• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Press Release: EpiVax Accelerates COVID-19 Vaccine Development with UGA’s Center for Vaccines and Immunology

Press Release: EpiVax Accelerates COVID-19 Vaccine Development with UGA’s Center for Vaccines and Immunology

by Adam | Mar 4, 2020 | News

PROVIDENCE, R.I., Mar. 4, 2020 – EpiVax Inc., a Rhode Island company, announces a collaboration to develop a novel coronavirus SARS-CoV-2 (COVID-19) vaccine with University of Georgia (UGA, Athens GA) vaccine expert Ted Ross (Director, Center for Vaccines and...
EpiVax devises ‘recipe’ for coronavirus vaccine – Providence Business News interview

EpiVax devises ‘recipe’ for coronavirus vaccine – Providence Business News interview

by Adam | Feb 21, 2020 | News

By Elizabeth Graham -February 21, 2020 2:35 am Find the full story here. Staying current on the frantic pace of the coronavirus outbreak means following reports by major news outlets for most people, but analysts at EpiVax Inc. are more interested in websites that...
EpiVax worked for 21 years to be able to make a vaccine in 24 hours!

EpiVax worked for 21 years to be able to make a vaccine in 24 hours!

by Adam | Feb 10, 2020 | News

COVID-19 Coverage EpiVax is dedicated to providing continuously updated information concerning COVID-19 vaccine efforts. For all updates, press releases, interviews and more please visit our official COVID-19 page. Click here UPDATE March 16, 2020:   As closures and...
Press release: EpiVax’s Novel Tregitope technology offers promising outcomes in the Treatment of Type 1 Diabetes

Press release: EpiVax’s Novel Tregitope technology offers promising outcomes in the Treatment of Type 1 Diabetes

by Adam | Nov 6, 2019 | News

Providence, November 6th 2019 EpiVax announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports EpiVax, Inc (“EpiVax”), a pioneer in immunoinformatics innovation, announces the publication of “Therapeutic administration of...
Press release: EpiVax’s Novel Tregitope technology offers promising outcomes in the Treatment of Type 1 Diabetes

Press Release: Chugai Renews License to EpiVax’s ISPRI In Silico Toolkit for Immunogenicity Assessment

by Adam | Oct 23, 2019 | News

Announced today, Chugai Pharmaceutical Co., Ltd. (“Chugai”), a member of the Roche Group, will extend the company’s licensed access to the Immunogenicity Screening and Protein Reengineering Interface (ISPRI) toolkit developed by EpiVax, Inc....
« Older Entries
Next Entries »

Recent Posts

  • EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    
  • Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy

Recent Comments

No comments to show.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

This website uses cookies and similar technologies to collect information about your website experience for advertising, analytics, and other purposes as described in our Privacy Policy.